Tuesday, December 20, 2016

riverfronttimes : declared in GlaxoSmithKline’s New Drug Challenges HIV Treatment Orthodoxy

This was collected by Lucy William

We will quote to you the news of the best health sites Like : "riverfronttimes" and the most famous medical experts : Sarah Fenske


daily : 2016-12-20 & on time : 15:23


as declared in





Lindenwood Wrestler Sentenced to 30 Years for HIV Exposure Will Get a New Trial


Lindenwood Wrestler Sentenced to 30 Years for HIV Exposure Will Get a New Trial
image uploaded by "riverfronttimes" site
Michael Johnson, shown in a 2013 Facebook photo.Citing "fundamental unfairness," Missouri's appeals court has overturned the 30-year sentence given to Michael Johnson, a Lindenwood University wrestler convicted of knowingly exposing his sexual partners to HIV The case is now kicked back to St. Charles County for a new trial.Johnson, then 21, was charged with five felony counts in 2013, with police alleging he failed to tell his sex partners that he was HIV positive.Johnson had appealed his sentence on two grounds — first, that phone calls he'd made from jail should not have been admitted into evidence, and second, that his sentence was "grossly disproportionate" to his alleged crimes.The court threw out Johnson's conviction on the phone calls, leaving the question of his sentence's fundamental fairness a moot point.In a unanimous fourteen-page decision by Presiding Judge James M. Dowd, the appellate justices blasted St. Charles County prosecutors for failing to disclose 24 hours worth of tapes of Johnson's phone calls until what was in effect the very morning of his criminal trial.
about the details read more from here


GlaxoSmithKline's New Drug Challenges HIV Treatment Orthodoxy


GlaxoSmithKline's New Drug Challenges HIV Treatment Orthodoxy
image uploaded by "wsj" site
LONDON—GlaxoSmithKline PLC's ViiV Healthcare announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company's audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.U.K.-based Glaxo said its HIV pill dolutegravir plus Johnson & Johnson's rilpivirine suppressed the virus as well as traditional three- or four-drug combinations in two identical,...
about the details read more from here


Broad-Led Study Finds Three New HIV Host Factors, Possible Drug Targets


Broad-Led Study Finds Three New HIV Host Factors, Possible Drug Targets
image uploaded by "genomeweb" site
NEW YORK (GenomeWeb) – A CRISPR/Cas9-based genome-wide screen has found five potential drug targets for HIV infection.Get the full storyThis story is freefor registered usersRegistering provides access to this and other free content.Already have an account?
about the details read more from here


To follow all the new news about

VIRUSES and INFECTIONS

No comments:

Post a Comment